VIA
TBPH icon

Virtus Investment Advisers’s Theravance Biopharma TBPH Stock Holding History

Virtus Investment Advisers’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
69,885
+23,421
+50% +$388K 0.28% 181
2026
Q1 		$754K Buy
46,464
+8,853
+24% +$157K 0.21% 169
2025
Q4 		$704K Sell
37,611
-4,273
-10% -$70.9K 0.19% 164
2025
Q3 		$612K Hold
41,884
– – 0.18% 187
2025
Q2 		$462K Buy
41,884
+5,505
+15% +$53.5K 0.16% 190
2025
Q1 		$325K Buy
+36,379
New +$339K 0.09% 236

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Virtus Investment Advisers's TBPH Position: Q2 2026 in Review

Virtus Investment Advisers increased its Theravance Biopharma (TBPH) stake by 50% in Q2 2026, buying an estimated $388K and bringing the position to 69,885 shares worth $1.19M. The position accounts for 0.28% of the portfolio, ranked #181.

Virtus Investment Advisers first reported a position in TBPH in Q1 2025 and has held it in 6 quarters since. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Virtus Investment Advisers held 69,885 shares of Theravance Biopharma worth $1.19M as of Q2 2026.
  • Virtus Investment Advisers bought 23,421 Theravance Biopharma shares in Q2 2026, an estimated $388K.
  • Theravance Biopharma made up 0.28% of Virtus Investment Advisers's portfolio in Q2 2026, its #181 holding.
  • Virtus Investment Advisers first reported a position in Theravance Biopharma in Q1 2025 and has held it in 6 quarters since.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.